USRE19608E - Process for the production of - Google Patents

Process for the production of Download PDF

Info

Publication number
USRE19608E
USRE19608E US19608DE USRE19608E US RE19608 E USRE19608 E US RE19608E US 19608D E US19608D E US 19608DE US RE19608 E USRE19608 E US RE19608E
Authority
US
United States
Prior art keywords
solution
anesthetic
injection
solutions
disodium phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
Publication date
Application granted granted Critical
Publication of USRE19608E publication Critical patent/USRE19608E/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids

Definitions

  • the anesthetic solution may be prepared by mixing a suprarenal gland preparation (for instance suprarenin) with anesthetic preparations, such as for instance p-aminobenzoyldiethyl-amino-ethanol hydrochloride (known as novocain), a-dimethyl amino-b-methyl butanol hydrochloride, benzoyl-ethyl-tetramethyl diamino-isopropanol hydrochloride. Solutions thus treated by adding sodium bicarbonate are unsatisfactory because they are unstable and become decomposed or cloudy in a very short time, so as to be unserviceable for injection.
  • a suprarenal gland preparation for instance suprarenin
  • anesthetic preparations such as for instance p-aminobenzoyldiethyl-amino-ethanol hydrochloride (known as novocain)
  • novocain p-aminobenzoyldiethyl-amino-ethanol hydrochloride
  • aqueous solvent and the other ingredients are kept separate in the respective compartments of such a receptacle, yet handy for immediate use in preparing a solution for injection.
  • composition is given, the quantities being understood as applying to 1 cubic centimeter 0! solution: .02 grams of p-aminobenzoyl diethyl amino ethanol hydrochloride (known as novocain, an anesthetic), .000036 grams of o-dioxyphenylethanolmethylamin bitartrate (known as epinephrine, adrenaline, or suprarenin), .003 grams of disodium phosphate (siirensen).
  • novocain an anesthetic
  • o-dioxyphenylethanolmethylamin bitartrate known as epinephrine, adrenaline, or suprarenin
  • disodium phosphate disodium phosphate
  • the step which consists in adding to an anesthetic solution containing epinephrine, an amount oi disodium phosphate suflicient to impart a slightly alkaline character to the solution.
  • the step which consists in adding to a solution of p-aminobenzoyl-diethyl-amino-ethanol hydrochloride containing epinephrine, an amount of disodium phosphate suflicient to impart a slightly alkaline character to the solution.
  • An anesthetic solution for hypodermic injection containing a solvent, an acid-containing anesthetic material for local anesthesia, epinephrine, and an alkaline bufier salt of a stable acid in sumcient quantity to impart a nearly neutral character to the solution.
  • An anesthetic composition to be mixed with water to produce an anesthetic solution comprising an acid-containing local anesthetic material, epinephrine, and an alkaline butter salt of a stable acid in suiiicient quantity to produce a nearly neutral condition in the resulting solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

Reissued June 11, 1935 UNITED STATES PATENT OFFICE PROCESS FOR THE PRODUCTION OF ANESTHETIC SOLUTIONS Max Woelm, Spangenberg,
assignor, by mesne assignments, to
near Kassel, Germany, Novocol Chemical Mfg. Co. Inc., Brooklyn, N. Y., a corporation of New York No Drawing. Original No. 1,916,089, dated June 1933, Serial No. 294,931, July 23, 1928. Ap-
plication for reissue flied April 8, 1935, Serial No. 14,445. In Germany May 2, 1927 Claims.
It is known (see for instance an article by Lawen and Gross in Miinchener Medizinische Wochenschriit 1910, No. 39) that the addition of sodium bicarbonate to such solutions of either 5 organic or synthetic suprarenal gland preparations as have an anesthetic effect and simultaneously render tissues bloodless, will reduce the acidity of the solution and render it more suitable for injection. The anesthetic solution may be prepared by mixing a suprarenal gland preparation (for instance suprarenin) with anesthetic preparations, such as for instance p-aminobenzoyldiethyl-amino-ethanol hydrochloride (known as novocain), a-dimethyl amino-b-methyl butanol hydrochloride, benzoyl-ethyl-tetramethyl diamino-isopropanol hydrochloride. Solutions thus treated by adding sodium bicarbonate are unsatisfactory because they are unstable and become decomposed or cloudy in a very short time, so as to be unserviceable for injection.
I have found that I can obtain non-irritating, stable, comparatively alkaline solutions 0! suprarenal gland preparations by adding disodium phosphate instead of the sodium bicarbonate above referred to. The disodium phosphate imparts a slightly alkaline character to the solutions and renders them stable for a sufficient length of time to permit their use for injection. The addition of a predetermined amount of the buffer disodium phosphate makes the acid anesthetic solution less acid so that it becomes nearly neutral and, with further additions, the solution passes to neutral and then, in the preferred form of the invention, becomes slightly alkaline (nearly neutral). When the solutions are rendered slightly alkaline they remain clear for at least ten minutes, which is a sufiicient length of time to permit the injection to be successfully accomplished.
In order to avoid with absolute certainty the decomposition of the alkali-sensitive bases, the individual ingredients intended for preparing the solution are kept separate until shortly before such solution is to be used. For storing these ingredients separately, in the proper proportions for producing the desired solution, I prefer to employ two-compartment flasks or receptacles of any suitable well-known or approved construction, such as for instance those disclosed in U. 5. Patents 1,570,346 and 1,592,632.
The aqueous solvent and the other ingredients (the latter in a dry condition) are kept separate in the respective compartments of such a receptacle, yet handy for immediate use in preparing a solution for injection.
As an example, the following composition is given, the quantities being understood as applying to 1 cubic centimeter 0! solution: .02 grams of p-aminobenzoyl diethyl amino ethanol hydrochloride (known as novocain, an anesthetic), .000036 grams of o-dioxyphenylethanolmethylamin bitartrate (known as epinephrine, adrenaline, or suprarenin), .003 grams of disodium phosphate (siirensen).
I claim:
1. In the process for the production of nonirritating anesthetic solutions stable for a sufficient length 01. time to permit of their use for injection, the step which consists in adding to an anesthetic solution containing epinephrine, an amount oi disodium phosphate suflicient to impart a slightly alkaline character to the solution.
2. In the process for the production of non irritating anesthetic solutions stable for a sumcient length of time to permit of their use for injection, the step which consists in adding to a solution of p-aminobenzoyl-diethyl-amino-ethanol hydrochloride containing epinephrine, an amount of disodium phosphate suflicient to impart a slightly alkaline character to the solution.
3. An anesthetic solution for hypodermic injection containing a solvent, an acid-containing anesthetic material for local anesthesia, epinephrine, and an alkaline bufier salt of a stable acid in sumcient quantity to impart a nearly neutral character to the solution.
4. An anesthetic solution 101' hypodermic injection containing water as a solvent, an acid salt oi procaine, epinephrine, and a suflicient quantity 40 of disodium phosphate to produce a nearly neutral solution.
5. An anesthetic composition to be mixed with water to produce an anesthetic solution comprising an acid-containing local anesthetic material, epinephrine, and an alkaline butter salt of a stable acid in suiiicient quantity to produce a nearly neutral condition in the resulting solution.
MAX WOELM.
US19608D Process for the production of Expired USRE19608E (en)

Publications (1)

Publication Number Publication Date
USRE19608E true USRE19608E (en) 1935-06-11

Family

ID=2083866

Family Applications (1)

Application Number Title Priority Date Filing Date
US19608D Expired USRE19608E (en) Process for the production of

Country Status (1)

Country Link
US (1) USRE19608E (en)

Similar Documents

Publication Publication Date Title
US2828212A (en) Stable dry curing salt compositions
US2580683A (en) Capsules filled with aqueous solutions and method of preparing the same
US2435744A (en) Flavoring solutions
DE19850830A1 (en) Process for the preparation of a solution, in particular a dialysis or infusion solution
USRE19608E (en) Process for the production of
GB2151203A (en) Compositions for making vesicles
US1916089A (en) Process for the production of anesthetic solutions
DE69837159T2 (en) PROCESS FOR PREPARING A SINGLE DOSE TIP WITH A LYOPHILIZED PROTEIN MIXTURE FOR THE ADMINISTRATION OF A VOLUME OF LESS THAN 0.5 ML
Buster et al. Serum steroid levels following a large intravenous dose of a steroid sulfate precursor during the second trimester of human pregnancy. II. Pregnenolone sulfate
JPS60258110A (en) Progesterone emulsified parenteral solution injectable intravenously
US2600344A (en) Androgenic composition
Stearns et al. Utilization of calcium salts by children
Porter et al. The culture of tissue cells in clots formed from purified bovine fibrinogen and thrombin.
WO2002026233B1 (en) Infusion of ciprofloxacin having reduced acid content and being stable in storage
JPH0639374B2 (en) Effervescent glycerin suppository
USRE19569E (en) Anaesthetic composition
US2790719A (en) Food flavor intensifier
US1741786A (en) Process of preparing medicines
US3344027A (en) Stable suspension of iron salts
Stewart Circulation of the human thyroid
DE259493C (en)
US1924685A (en) Anesthetic composition
US2751327A (en) Preparation of hair treating compositions in solid form
ES396666A1 (en) Toothpaste composition
US2438880A (en) Riboflavin solution